

DAFTAR PUSTAKA

1. World Health Organization. Cardiovascular Disease (CVDs). 2017 (updated 17 May 2017;cited 23 September 2020) Available from:[https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)).
2. RISKESDAS. Hasil Utama RISKESDAS 2018. Jakarta: Kementerian Kesehatan Republik Indonesia. 2018;0:1-57.
3. Ibanez B and James S. The 2017 ESC STEMI Guidelines. *European Heart Journal*. 2018;39:79-82.
4. Libby P. The Vascular Biology of Atherosclerosis. In: Z. D. Mann DL, Libby P, Bonow RO, ed. *Braunwald's Heart Disease*. 10 ed. Philadelphia: Elsevier Saunders; 2015: 873-888.
5. Sianos GM, Serruys PW. Angiographic Thrombus Burden Classification in Patients with ST-Segment Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention. *Journal of Invasive Cardiology*. 2010;22:6B-14B.
6. Salajegheh A. *Heparanase Angiogenesis in Health, Disease and Malignancy* Switzerland: Springer International Publishing; 2016: 141-144.
7. Jin H, Cui M and Hu SX. New findings of heparanase in human diseases. *Eur Rev Med Pharmacol Sci*. 2019;23:5999-6004.
8. Tatour M, Shapira M, Axelman E, Ghanem S, Keren-Politansky A, Bonstein L, Brenner B and Nadir Y. Thrombin is a selective inducer of heparanase release from platelets and granulocytes via protease-activated receptor-1. *Thromb Haemost*. 2017;117:1391-1401.
9. Gutter-Kapon L, Shaked Y, Li JP, Aronheim A, Ilan N, Vlodaysky I. Heparanase is required for activation and function of macrophages. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113.
10. Osterholm C, Lengquist M, Ponten F, Renne T, Li JP, Hedin U. Increased Expression of Heparanase in Symptomatic Carotid Atherosclerosis. *Atherosclerosis*. 2013;226:67-73.
11. Gurbuz AS, Efe SC, Yilmaz MF, Yanik RE, Yaman A, Kirma C. Heparanase is a predictive marker for high thrombus burden in patients with ST-segment elevation myocardial infarction. *Biomarkers*. 2019;24:600-606.
12. Bayam E, Kalcik M, Gurbuz AS, Yesin M, Guner A, Gunduz S, Gursoy MO, Karakoyun S, Cersit S, Kilicgedik A, Candan O, Yaman A and Ozkan M. The relationship between heparanase levels, thrombus burden and thromboembolism in patients receiving unfractionated heparin treatment for prosthetic valve thrombosis. *Thromb Res*. 2018;171:103-110.
13. Baker AB, Gibson WJ, Kolachalama VB, Golomb M, Indolfi L, Spruell C, Zcharia E, Vlodaysky I and Edelman ER. Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. *J Am Coll Cardiol*. 2012;59:1551-60.
14. Gurbuz AS, Efe SC, Yilmaz MF, Yanik RE, Yaman A, Kirma C. Heparanase is a predictive marker for high thrombus burden in patients with ST-segment elevation myocardial infarction. *Biomarkers*. 2019;24:600-606.

14. Falk BJ. New and Emerging Insights into the Pathobiology of Acute Myocardial Infarction *Myocardial Infarction A Companion to Braunwald's Heart Disease* Missouri: Elsevier; 2017: 22-23.
15. Asada Y, Yamashita A, Sato Y, Hatakeyama. Pathophysiology of atherothrombosis: Mechanisms of thrombus formation on disrupted atherosclerotic plaques. *Pathology International*. 2020;70:309-322.
16. Badimon L. Thrombosis formation on atherosclerotic lesions and plaque rupture. *Journal of Internal Medicine*. 2014;276:618-632.
17. Badimon IB, Fuster V, Badimon L. Coronary Thrombosis: Local and Systemic Factors. In: H. R. Fuster V, Narula J, Eapen ZJ, ed. *Hurts's The Heart*. 14th ed. New York: McGraw-Hill Education; 2017(1): 880-891.
18. Stone GW, Maehara A, Witzenbichler B, Godleski J, Parise H, Dambrink JH. Intracoronary Abciximab and Aspiration Thrombectomy in Patients with Large Anterior Myocardial Infarction. *JAMA*. 2012;307:1817-1826
19. Tanboga IH, Aksakal E, Kalkan K, Sevimli S, Acikel M. Determinants of Angiographic Thrombus Burden in Patients with ST-Segment Elevation Myocardial Infarction. *Clinical and Applied Thrombosis/Hemostasis*. 2014;20:716-722.
20. Irmalita JD, Andrianto, Stianto BY, Tobing DP, Firman D, Firdaus I. Pedoman Tatalaksana Sindrom Koroner Akut *Pedoman Tatalaksana Sindrom Koroner Akut*; 2015: 1-88.
21. Topol E. Acute Myocardial Infarction: Early Diagnosis and Management *Textbook of Cardiovascular Medicine* Philadelphia: Lippincott Williams and Wilkins; 2007: 280-281.
22. Scarparo P, Gamera M, Wilschut J, Daemen J, Dekker W, Zijlstra F, et al. Impact of thrombus burden on long term clinical outcomes in patients with either anterior or non-anterior ST-segment elevation myocardial infarction. *Journal of Thrombosis and Haemostasis*. 2021;0:1-11.
23. Jolly S, Lavi S, Cantor WJ, Bernat I, Cheema A, et al. Thrombus Aspiration in Patients with High Thrombus Burden in the TOTAL trial. *Journal of the American College of Cardiology*. 2018;72:1589-1596.
24. Li JP. Heparin, heparan sulfate and heparanase in inflammatory reaction. *Thrombosis and Haemostasis*. 2009;102:823-828.
25. Wang F, Rodrigues B. The Function of Heparanase in Diabetes and its Complications. *Canadian Journal of Diabetes*. 2013;37:332-338.
26. Wu L and Davies GJ. An Overview of the Structure, Mechanism and Specificity of Human Heparanase. *Adv Exp Med Biol*. 2020;1221:139-167.
27. Parish CR. Heparan sulfate and inflammation. *Nature Immunology*. 2005;6:861-862.
28. Vlodaysky I, Barash U, Nguyen HM, Yang SM and Ilan N. Biology of the Heparanase-Heparan Sulfate Axis and Its Role in Disease Pathogenesis. *Semin Thromb Hemost*. 2021;47:240-253.
29. Elli S and Guerrini M. Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin. *Adv Exp Med Biol*. 2020;1221:169-188.
30. Wang F, Pulinilkunnit T, Flibotte S, Nislow C, Vlodaysky I, Hussein B and Rodrigues B. Heparanase protects the heart against chemical or ischemia/reperfusion injury. *J Mol Cell Cardiol*. 2019;131:29-40.

31. Aldi S, Eriksson L, Kronqvist M, Lengquist M, Lofling M, Folkersen L, Matic LP, Maegdefessel L, Grinnemo KH, Li JP, Osterholm C and Hedin U. Dual roles of heparanase in human carotid plaque calcification. *Atherosclerosis*. 2019;283:127-136.
32. Syafri M. Analisis Hubungan antara Heparanase dengan TGF a, IL-17 dan NFKB pada Pasien Infark Miokard Akut dengan Elevasi Segmen ST. *Program Studi S3 Biomedik*. 2020.
33. Crispel Y, Ghanem S, Attias J, Kogan I, Brenner B and Nadir Y. Involvement of the heparanase procoagulant domain in bleeding and wound healing. *J Thromb Haemost*. 2017;15:1463-1472.
34. Gurbuz AS, Ozturk S, Efe SC, Yilmaz MF, Yanik RE, Yaman A and Kirma C. Serum Heparanase Level Is Decreased in Stable Coronary Artery Disease. *Med Princ Pract*. 2019;28:573-580.
35. Nadir Y. Heparanase in the Coagulation System. *Adv Exp Med Biol*. 2020;1221:771-784.
36. Shantsila E LG. *Non-Vitamin K Antagonist Oral Anticoagulants: A Concise Guide*. Adis: Springer; 2016.
37. Weitz JI. Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease. In: L. P. Z. D. Mann DL, Bonow RO, ed. *Braunwald's Heart Disease Philadelphia: Elsevier Saunders*; 2015(10): 1809-1832.
38. Nadir Y. Heparanase in the Coagulation System. *Adv Exp Med Biol*. 2020;1221:771-784.
39. Buijsers B, Yanginlar C, de Nooijer A, Grondman I, Maciej-Hulme ML, Jonkman I, et al. Increased Plasma Heparanase Activity in COVID-19 Patients. *Front Immunol*. 2020;11:575047.
40. Xia J, Sheng W, Pei L, Li N, Zhang Z, Wang J, et al. Effects of unfractionated heparin and rivaroxaban on the expression of heparanase and fibroblast growth factor 2 in human osteoblasts. *Mol Med Rep*. 2017;16:361-366.
41. Nasser N.j. Sarig BB, Nevo E, Goldshmidt O, Zcharia E, Vlodaysky I. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. *Journal of Thrombosis and Haemostasis*. 2006;4:560-565.
42. Vlodaysky I, Iozzo RV and Sanderson RD. Heparanase: multiple functions in inflammation, diabetes and atherosclerosis. *Matrix Biol*. 2013;32:220-2.
43. Hardisman. *Tanya Jawab Metodologi Penelitian Kesehatan*. Yogyakarta: Gosyen Publishing; 2021.
44. Sastroasmoro S. Dasar-dasar metodologi penelitian klinis. Edisi 5 ed. Jakarta: Sagung Seto; 2016. p. 247-248.
45. Sianos PM, Daemen J, Vaina S, Mieghem CA, Domburg RT, et al. Angiographic Stent Thrombosis After Routine Use of Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction. *Journal of the American College of Cardiology*. 2007;50:573-578.
46. Wendelboe RG. Global Burden of Thrombosis. *Circulation Research*. 2016;118:1340-1347.
47. Heer HM, Schmidt K, Mehili J, Zahn R, Kuck KH, et al. Sex Differences in Percutaneous Coronary Intervention-Insight from the Coronary

- Angiography and PCI Registry of the German Society of Cardiology. *Journal of the American Heart Association*. 2017;6:e004972.
48. Mora LP, Ridker PM. Primary Prevention of Cardiovascular Disease. In: B. R. Libby P, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD, ed. *Braundwald's Heart Disease* Philadelphia: Elsevier; 2022(12).
 49. Vicent RJ, Masa MJ, Delhoyo FD, Saldivar HG, Bruna V, et al. Predictor of high Killip class after ST segment elevation myocardial infarction in the era of primary reperfusion. *International Journal of Cardiology*. 2017;248:46-50.
 50. Blich GA, Arvatz G, Sebbag A, Shafat I, Sabo E, et al. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. *Atherosclerosis and Thrombosis Vascular Biology*. 2013;33:56-65.
 51. Dangas GD WJ, Giustino G, Makkar R, Mehran R. Prosthetic Heart Valve Thrombosis. *Journal of the American College of Cardiology*. 2016;68:2670-2689.
 52. Yilmaz MF, Acar E, Inanir M, Karabay CY and Izgi IA. Serum heparanase levels and left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. *Herz*. 2021.
 53. Tan LG. Red vs White Thrombi: Treating the Right Clot is Crucial. *Archives of Internal Medicine*. 2003;163:2534-2535.
 54. Kirbis BU, Sabovic M, Zupan I, Sinkovic A. Inflammation markers in patients with coronary artery disease-comparison of intracoronary and systemic levels. *Wiener Klinische Wochenschrift*. 2010;122:31-34.

